Company

Pfizer Inc.

Pfizer is a research-based global biopharmaceutical company that discovers, develops, manufactures, markets and sells biopharmaceutical products worldwide. ↗

Headquarters	New York, NY ↗
Leadership	Albert Bourla, Chairman and CEO ↗
Employees	approximately 75,000 ↗
Revenue	$62.6 billion (fiscal 2025) ↗
Department of War obligations	$18.5 billion in prime contracts since fiscal 2022 ↗
Ownership	Incorporated in Delaware, June 2, 1942 ↗
Shares	PFE ↗

Products

Eliquis is a Pfizer cardiovascular metabolic medicine in its internal medicine portfolio. ↗
The Prevnar family and Comirnaty are among Pfizer's vaccines for all ages. ↗
Paxlovid is Pfizer's treatment for COVID-19. ↗
Ibrance, Xtandi and Padcev are among Pfizer's oncology medicines. ↗
Pfizer's rare disease portfolio includes the Vyndaqel family, which it markets alongside Genotropin and Hympavzi. ↗
Xeljanz and Cibinqo are among Pfizer's inflammation and immunology medicines. ↗

Acquisitions

Pfizer acquired Metsera, an obesity and cardiometabolic drug developer, on November 13, 2025, for $65.60 per share in cash plus a contingent value right of up to $20.65 per share. ↗
Pfizer acquired Seagen, a cancer medicines company, on December 14, 2023, for $229 per share in cash. ↗

Segments

Pfizer runs three operating segments: Biopharma, PC1 and Pfizer Ignite, with Biopharma the only reportable segment. ↗
PC1 is Pfizer's contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. ↗